Aura Biosciences, Inc. filed a Current Report on Form 8-K with the SEC on November 9, 2026, announcing its financial results for the quarter ended September 30, 2026, and an updated corporate presentation.

Key Highlights

  • Quarterly results announced: The company issued a press release on November 9, 2026, covering financial results for the quarter ended September 30, 2026.
  • Corporate presentation updated: The company updated its corporate presentation on November 9, 2026, for use in meetings with investors, analysts, and others.
  • Cash runway guidance: The filing references the company's expected cash runway into the first half of 2029, as a forward-looking statement.
  • Key product candidate: The filing references belzupacap sarotalocan ("bel-sar") in the context of forward-looking statements about patient quality of life and treatment paradigm changes.
  • Emerging growth company: Aura Biosciences is designated as an emerging growth company under applicable securities rules, according to the filing.
  • Signed by CEO: The filing was signed by Natalie Holles, Chief Executive Officer and President, as Principal Executive Officer.

Aura Biosciences Discloses Q3 2026 Results and Updated Investor Presentation

Aura Biosciences, Inc. (NASDAQ:AURA), a clinical-stage biopharmaceutical company headquartered at 80 Guest Street, Boston, Massachusetts, filed a Current Report on November 9, 2026, disclosing two items. Under Item 2.02, the company reported that it issued a press release on November 9, 2026, announcing financial results for the fiscal quarter ended September 30, 2026. That press release is furnished as Exhibit 99.1 and, according to the filing, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.

Under Item 8.01, the company disclosed that it updated its corporate presentation on November 9, 2026, for use in meetings with investors, analysts, and others. That presentation was filed as Exhibit 99.2 and, unlike the press release, is filed for purposes of Section 18 of the Exchange Act, according to the filing.

The filing includes a cautionary note regarding forward-looking statements, identifying several subjects the company characterizes as forward-looking, including statements about its research and development programs, clinical trial timing and progress, the product candidate bel-sar, regulatory approval prospects, commercialization plans, and the company's expected cash runway into the first half of 2029. The company stated that such forward-looking statements involve known and unknown risks and uncertainties, and that actual results may differ materially from those expressed or implied. The filing directs readers to risk factors described in the company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for additional detail.

What Was Disclosed

Aura Biosciences filed a Current Report on November 9, 2026, covering Q3 2026 financial results via a press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2), along with standard forward-looking statement cautionary language referencing its bel-sar program and expected cash runway.